At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 50 enrolled
Drug / intervention
Typherix +1 morebiological
Likely dose
Typherix 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.
In Brief
A Phase 1 clinical trial evaluating Typherix and NVGH Vi-CRM197 for Typhoid Fever. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTyphoid Fever
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionJun 2010
Study CompletionNov 2010
TodayJul 2026
First PostedMay 14, 2010
Enrollment StartMay 1, 2010
Primary CompletionJun 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.1 years ago
Interventions
Typherixbiological
1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
NVGH Vi-CRM197biological
1 dose of 0.5 mL containing 25 mcg of Vi-CRM